Amphastar Pharmaceuticals Cash Flow from Operating Activities 2012-2026 | AMPH
Amphastar Pharmaceuticals cash flow from operating activities from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
|
Amphastar Pharmaceuticals Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $156 |
| 2024 | $213 |
| 2023 | $184 |
| 2022 | $89 |
| 2021 | $98 |
| 2020 | $57 |
| 2019 | $42 |
| 2018 | $38 |
| 2017 | $39 |
| 2016 | $39 |
| 2015 | $11 |
| 2014 | $21 |
| 2013 | $31 |
| 2012 | $-2 |
| 2011 | $19 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |